Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteersDavid G. Soergel, Lynn R. Webster, Ruth Ann Subach et al.|Pain|2014Cited by 264
A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute painEugene R. Viscusi, Franck Skobieranda, Lynn R. Webster et al.|Pain|2015Cited by 209
APOLLO‐2: A Randomized, Placebo and Active‐Controlled Phase <scp>III</scp> Study Investigating Oliceridine ( <scp>TRV</scp> 130), a G Protein–Biased Ligand at the μ‐Opioid Receptor, for Management of Moderate to Severe Acute Pain Following AbdominoplastyNeil Singla, Eugene R. Viscusi, Franck Skobieranda et al.|Pain Practice|2019Cited by 183
<p>APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the &micro;-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy</p>Eugene R. Viscusi, Neil Singla, Franck Skobieranda et al.|Journal of Pain Research|2019Cited by 165
Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexyRichard Bogan, Karel Šonka, Michael J. Thorpy et al.|SLEEP|2020Cited by 72